First-line treatment for patients with advanced non-small cell lung carcinoma and high PD-L1 expression: pembrolizumab or pembrolizumab plus chemotherapy

Pembrolizumab monotherapy has become the preferred treatment for patients with advanced non-small cell lung carcinoma (NSCLC) and a programmed cell death-ligand 1 (PD-L1) tumor proportion score (TPS) of at least 50%. However, little is known about the value of adding chemotherapy to pembrolizumab in...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Immunother Cancer
Main Authors: Zhou, Yixin, Lin, Zuan, Zhang, Xuanye, Chen, Chen, Zhao, Hongyun, Hong, Shaodong, Zhang, Li
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2019
Assuntos:
Commentary
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6500047/
https://ncbi.nlm.nih.gov/pubmed/31053172
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40425-019-0600-6
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados